Renaissance Technologies’s Alnylam Pharmaceuticals ALNY Stock Holding History

Renaissance Technologies’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-64,400	Closed	-$5.64M	–	3357
2018 Q3	$5.64M	Sell	64,400 -311,000	-83%	-$31.3M	0.01%	1726
2018 Q2	$37M	Buy	375,400 +140,000	+59%	+$13.9M	0.04%	579
2018 Q1	$28M	Buy	235,400 +227,300	+2,806%	+$29.3M	0.03%	746
2017 Q4	$1.03M	Buy	+8,100	New	+$1.02M	﹤0.01%	2651
2017 Q2	–	Sell	-51,100	Closed	-$2.62M	–	3175
2017 Q1	$2.62M	Buy	+51,100	New	+$2.36M	﹤0.01%	2094
2016 Q3	–	Sell	-18,673	Closed	-$1.04M	–	3305
2016 Q2	$1.04M	Sell	18,673 -195,327	-91%	-$12.3M	﹤0.01%	2518
2016 Q1	$13.4M	Buy	+214,000	New	+$14.2M	0.03%	929
2015 Q3	–	Sell	-102,399	Closed	-$12.3M	–	3143
2015 Q2	$12.3M	Buy	+102,399	New	+$12.2M	0.03%	816
2014 Q2	–	Sell	-158,700	Closed	-$10.7M	–	2763
2014 Q1	$10.7M	Buy	+158,700	New	+$12.3M	0.03%	827

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Renaissance Technologies's ALNY Position: Q4 2018 in Review

Renaissance Technologies sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2018, closing a stake of 64,400 shares — an estimated $5.64M sold.

Renaissance Technologies first reported a position in ALNY in Q1 2014 and held it in 9 quarters. The position peaked at $37M in Q2 2018. 284 funds tracked by Wall St. Rank hold ALNY as of Q4 2018.

Renaissance Technologies reported no remaining Alnylam Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Renaissance Technologies sold 64,400 Alnylam Pharmaceuticals shares in Q4 2018, an estimated $5.64M.
Renaissance Technologies first reported a position in Alnylam Pharmaceuticals in Q1 2014 and held it in 9 quarters.
Renaissance Technologies's Alnylam Pharmaceuticals position peaked at $37M in Q2 2018.
284 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2018.

Based on Renaissance Technologies's 13F filing for Q4 2018, filed 13 Feb 2019.